Abstract
5566 Background: Several multi-targeted tyrosine kinase inhibitors (TKIs) have activity in RAI-refractory thyroid; anti-tumor effect attributed at least in part to their ability to inhibit angiogenesis in these vascular tumors. VEGF Trap (VT) is a recombinantly-produced fusion protein consisting solely of human sequences for vascular endothelial growth factor receptors 1 and 2 (VEGFR-1 and VEGFR-2) extracellular domains and human immunoglobulin IG1.VT has a good rationale for study in RAI-refractory thyoid cancers, and allows for a a more precise assessment of the role of angiogensis inhibition as a treatment strategy in these tumors. Methods: The study was a single institution, phase II, Simon 2-stage design [21->41 patients (pts)] based on objective response rate/6 month progression-free survival as the primary endpoints. Eligible pts have progressive, RAI-refractory/fluorodeoxyglucose (18-F)-avid, recurrent/metastatic, non-medullary, non-anaplastic thyroid cancer; RECIST measurable disease; and adequat...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
